Introduction
============

Hepatitis E virus (HEV) infection is an important public health problem in the developing world and presents two major issues. According to the fact sheet on hepatitis E, published by the World Health Organization (WHO) and updated in June 2014, there are each year 20 million hepatitis E infections, over 3 million acute cases of hepatitis E, and 56 600 hepatitis E-related deaths, with the highest prevalence in East- and southern Asia \[[@gov042-B1]\]. In the developed countries, hepatitis E infection is an emerging disease. It was traditionally thought to occur in individuals travelling to areas where the disease is endemic; however, cases of sporadic autochthonous hepatitis E have been reported in individuals with no history of recent travel \[[@gov042-B2]\]. In a recent analysis of the National Health and Nutrition Evaluation Survey (NHANES), the seroprevalence of hepatitis E in the USA was estimated at 6%, despite the rarity of reported cases of hepatitis E \[[@gov042-B3]\]. Its seroprevalence in blood donors in the United Kingdom is estimated to be 11% \[[@gov042-B4]\]. In the Toulouse region in south-west France---an area in which the disease is considered to be hyperendemic---the seroprevalence in blood donors was initially thought to be 16%, but rose to 52% using more sensitive assays \[[@gov042-B5]\].

HEV can cause asymptomatic, icteric, or fulminant acute hepatitis \[[@gov042-B6]\]. Cases of chronic hepatitis E were first reported in 2008 \[[@gov042-B7]\]. Chronic hepatitis has been described in HEV genotype 3 infection, which occurs in western Europe and North America, almost exclusively among immunosuppressed individuals. Some patients with chronic hepatitis E develop progressive liver disease, resulting in advanced fibrosis or cirrhosis \[[@gov042-B8]\].

In immunocompetent individuals, acute hepatitis E is diagnosed, based on the detection of anti-HEV immunoglobulin M (IgM), increased titers of anti-HEV immunoglobulin G (IgG), or detection of HEV RNA in blood or stool. In immunocompromised individuals, acute hepatitis E is diagnosed, based on detection of HEV RNA in blood or stool \[[@gov042-B9]\]. Given that serological techniques vary in their accuracy \[[@gov042-B10]\], some authors recommend confirming serologically-detected cases with molecular techniques (HEV RNA) \[[@gov042-B11]\]. Chronic hepatitis E is defined by persistent HEV replication for more than 6 months, or more than 3 months in the setting of organ transplantation \[[@gov042-B12]\].

The number of papers published on HEV infection and indexed in PubMed has increased substantially during the last decade. Numerous extra-hepatic manifestations are reported in association with acute or chronic hepatitis E \[[@gov042-B13]\]. Although causality is uncertain \[[@gov042-B14]\], the temporal association between HEV infection and the extra-hepatic manifestations, plus the exclusion of other possible etiologies suggest that HEV infection may be causal. These extra-hepatic manifestations can overshadow the hepatic injury and HEV may not be suspected. The aim of this article is to comprehensively review the published literature on extra-hepatic manifestations associated with HEV infection.

Search strategy and selection criteria
======================================

Two independent investigators (FB and SH) searched PubMed on March 25, 2015 using the MeSH term "hepatitis E" AND each of the following MeSH terms: "pancreatitis", "Guillain-Barre syndrome", "brachial plexus neuritis", "peripheral nervous system diseases", "meningitis", "encephalitis", "myelitis", "myositis", "arthralgia", "glucosephosphate dehydrogenase deficiency", "anemia", "thrombocytopenia", "agranulocytosis", "macrophage activation syndrome", "monoclonal gammopathy", "glomerulonephritis", "renal insufficiency", "cryoglobulinemia", "Schöenlein-Henoch purpura", "myasthenia gravis", "thyroiditis", "hyperthyroidism", and "myocarditis". No language or date restrictions were set in these searches. Searches retrieving articles with non-A, non-B hepatitis were excluded. Additional articles were sourced manually by searching the bibliographies of relevant articles. The extra-hepatic manifestations associated with HEV infection found in these searches were classified into different categories as shown in [Table 1](#gov042-T1){ref-type="table"}. There were no disagreements between the two investigators regarding the search results. An example of inter-investigator discussion was the choice of acute pancreatitis classification (mild, moderately severe, or severe) based on Revision of the Atlanta classification. Another example was discussion of duplicated cases of neurological manifestations and making sure that no duplicates were added to the manuscript. Table 1.Extra-hepatic manifestations of HEV infectionManifestationTypeAcute pancreatitisNeurologicalCentral nervous system diseasesMeningitis **-** encephalitis **-** meningoencephalitisAtaxiaPyramidal syndromePseudotumor cerebriAcute transverse myelitisPeripheral nervous system diseasesGuillian-Barre syndromeNeuralgic amyotrophyCranial nerve diseases: Bell palsy **-** oculomotor palsyMusculoskeletalNecrotizing myositisPyomyositisHematologicalHemolytic anemiaAplastic anemiaPure red-cell aplasiaSevere thrombocytopeniaHemophagocytic syndromeMGUSG6PD deficiencyAuto-immuneRenalDecreased eGFRGlomerulonephritis ± cryoglobulinemiaMembranous glomerulonephritisMembranoproliferative glomerulonephritisIgA nephropathyNephroangiosclerosisOther immune-mediatedThyroiditisMyocarditisHenoch--Schönlein purpuraMyasthenia gravis[^1]

Acute pancreatitis
==================

Acute pancreatitis (AP) in the setting of fulminant viral hepatitis is well recognized, and mortality depends on the severity of hepatitis, rather than pancreatitis \[[@gov042-B15], [@gov042-B16]\]. AP is rarely associated with non-fulminant viral hepatitis. Most frequently, these cases are attributed to hepatitis A virus (HAV), hepatitis B virus (HBV) or hepatitis C virus (HCV) \[[@gov042-B17]\]. The first documented case of non-fulminant HEV-associated AP was reported in 1999 by Mishra *et al*.** \[[@gov042-B18]\], along with five other cases of HAV-related AP. To the best of our knowledge, at least 13 other case reports \[[@gov042-B19]\] and 4 case series \[[@gov042-B32]\] have been reported, with a total of 56 patients ([Table 2](#gov042-T2){ref-type="table"}). One study was in the form of an abstract \[[@gov042-B34]\], and all others were original articles. Two of the case series were prospective \[[@gov042-B33], [@gov042-B35]\], and the other two were retrospective \[[@gov042-B32], [@gov042-B34]\]. Three patients were excluded: one patient had other plausible causes of AP (including medications) \[[@gov042-B29]\], and two patients had fulminant acute hepatitis E according to the criteria in the position paper on acute liver failure, published by the American Association for the study of Liver Diseases \[[@gov042-B34]\]. All cases fulfilled the criteria of the American College of Gastroenterology for the diagnosis of AP \[[@gov042-B37]\]. Table 2.Acute pancreatitis (AP) associated with non-fulminant acute hepatitis EAuthors/yearCountryNo. of casesAge/ sexHEV diagnosis /genotypeDays to AP[^a^](#gov042-TF1){ref-type="table-fn"}Days in hospital for AP[^b^](#gov042-TF2){ref-type="table-fn"}Severity of APTreatment of APOutcome**Case report**Mishra 1999 \[[@gov042-B18]\]India114/MIgM/NT104MildSupportiveRecoveryMajumder 1999 \[[@gov042-B25]\]India132/MIgM/NT15NMModerately severeSurgeryRecoveryBorgohain 2000 \[[@gov042-B19]\]India118/MIgG**-**IgM/NT09MildSupportiveRecoveryMaity 2002 \[[@gov042-B24]\]India118/MIgM/NT3035SevereHemodialysisRecoveryMakharia 2003 \[[@gov042-B26]\]India145/MIgM/NT0NMMildSupportiveRecoveryJaroszewicz 2005 \[[@gov042-B21]\] [^c^](#gov042-TF3){ref-type="table-fn"}Poland128/MIgM/NT156MildSupportiveRecoveryThapa 2009 \[[@gov042-B31]\] [^d^](#gov042-TF4){ref-type="table-fn"}India17/MIgM/NT1229MildSupportiveRecoverySomani 2009 \[[@gov042-B30]\]India135/MIgM/NT720SevereHemodialysisDeathDeniel 2011 \[[@gov042-B20]\] [^e^](#gov042-TF5){ref-type="table-fn"}France126/MIgM-PCR/1a21NMModerately severeSupportiveRecoveryJavid 2012 \[[@gov042-B22]\]India136/MIgG**-**IgM/NT75MildSupportiveRecoveryRudrajit 2013 \[[@gov042-B28]\]India124/MIgM/NT166MildSupportiveRecoveryNayak 2013 \[[@gov042-B27]\]India116/MIgM-PCR/NT89mildSupportiveRecoveryKaranth 2014 \[[@gov042-B23]\]India127/MIgG**-**IgM**-**PCR/NT2814severeSupportiveRecovery**Case series**Jain 2007 \[[@gov042-B33]\]India4mean 26IgM/NT4 (2**--**5)6 (3**--**12)4 mild4 supportiveRecovery4 menBhagat 2008 \[[@gov042-B32]\]India4mean 21IgM/NT15 (12**--**17)12 (7**--**23)2 mild3 supportiveRecovery3M/1F2 moderately severe1 drainageSudhamshu 2011 \[[@gov042-B35]\]Nepal17NMIgM/NTNMNM16 mild/moderate1 hemodialysis1 death1 severe16 supportive16 recoveryMohindra 2013 \[[@gov042-B34]\]India15mean 25IgM/NT8 (0**--**35)7 (2**--**30)5 mild15 supportive15 recovery14M/1F5 moderately severe5 severe**Total**51 southern Asia53mean 24.6 35M/2F49 IgM10 (0**--**35)9 (2**--**35)44 mild/moderate47 supportive2 deaths1 France1 IgG + IgM9 severe2 surgery51 recovery1 Poland3 IgM + PCR[^2][^3][^4][^5][^6][^7]

Of the 53 included patients, 51 were from southern Asia (India and Nepal) and 2 were from western countries, although both had recently travelled to southern Asia \[[@gov042-B20], [@gov042-B21]\]. The mean age of patients at diagnosis was 24.6 years (range 7--54) with a male-to-female ratio of 18:1. The diagnosis of acute HEV was based on the presence of anti-HEV IgM in 49 patients, anti-HEV IgG and anti-HEV IgM in 1 patient, and anti-HEV IgM and HEV RNA in 3 patients. Genotyping was performed in one patient and revealed type 1a \[[@gov042-B20]\]. It is presumed that all other patients were infected with genotype 1, which is prevalent in that area; it is possible that genotype 1 has high tropism for the pancreas. So far, no cases of AP have been reported in patients infected with other HEV genotypes. Although the presumption that all these patients were infected with genotype 1 may be justified, there is also a possibility that other genotypes may be associated with AP; however---as is the case of fulminant acute hepatitis E, which has been increasingly reported in western Europe, where genotype 3 is prevalent---AP related to acute hepatitis E may occur in these regions as well.

The mean interval between jaundice and AP-pain was 10 days (range 0--35). The mean hospital stay for AP was 9 days (range 2--35). We retrospectively classified these AP cases into mild, moderately severe, or severe, based on Revision of the Atlanta Classification \[[@gov042-B38]\], as it is currently the most widely accepted set of criteria. AP was mild or moderately severe in 44 patients (83%) and severe in 9 patients (17%). Mild pancreatitis was not evaluated in a major prospective study of these cases \[[@gov042-B35]\], which may have resulted in a selection bias favoring the diagnosis of more severe cases. The overall mortality rate was 3.8% (2 of 53 patients) which is similar to the mortality rate observed for all other causes of AP.

The typical profile is a 25-year-old male residing in southern Asia, developing acute pancreatitis 10 days after the onset of jaundice, usually resolving with supportive treatment, with greater severity than previously thought, but with a similar mortality rate to other causes of AP.

Severe abdominal pain early in the course of acute hepatitis E should alert the clinician to the possibility of associated AP. Early diagnosis of AP complicating acute hepatitis E may help in reducing morbidity and mortality. Despite the rarity of the association between AP and non-fulminant acute hepatitis E, HEV infection should be added to the potential etiologies of AP in areas where the disease is endemic.

Neurological manifestations of HEV
==================================

Neurological manifestations of HEV infection were first reported by Soud in 2000 \[[@gov042-B39]\]. We are aware of 42 subsequent reports, involving a total of 77 patients, from regions where the disease is endemic and others where it is not, of neurological manifestations associated with HEV infection \[[@gov042-B40]\] ([Table 3](#gov042-T3){ref-type="table"}). Table 3.Neurological manifestations associated with HEV infectionAuthors/yearCountryNo. of casesAge/sexNeurological manifestationsDelay hepatitis neurological disordersIgMHEV RNAHEV genotypeALT (IU/L)TreatmentRecovery/delay**Acute hepatitis E -- Peripheral manifestations**Sood 2000 \[[@gov042-B39]\]India150/MGBS5 days+NTNT114SupportiveFull/1 monthKumar 2002 \[[@gov042-B45]\]India135/MGBS17 days+NTNT752MV/IVIGFull/2 weeksKamani 2005 \[[@gov042-B46]\]India158/FGBS9 days+NTNT1448IVIG/PPFull/12 daysKhanam 2008 \[[@gov042-B47]\]Bangladesh120/MGBS10 days+NTNT2509MVFull/12 daysLoly 2009 \[[@gov042-B48]\]Belgium166/MGBS GM2+Few days+NTNT1813IVIGFull/3 monthsChalupa 2010 \[[@gov042-B49]\]Czech Rep165/MGBSNo delay for all+NTNT1600IVIGFull/4 monthsKamar 2011 \[[@gov042-B40]\]France160/FGBSConcomitant+Serum+CSF--3f384IVIGPartial/18 monthsCronin 2011 \[[@gov042-B50]\]Ireland140/MGBS GM2+Concomitant+NTNT57MV/IVIG/PPFull/6 monthsMaurissen 2012 \[[@gov042-B51]\]Belgium151/FGBS GM1 & 2+Concomitant+Serum+NT2074IVIGFull/1 weekTse 2012 \[[@gov042-B52]\]Hong Kong160/FGBS3 days+NTNT2858PPFull/1 monthDel Bello 2012 \[[@gov042-B53]\]France165/MGBS, severe myositisConcomitant+Serum+3f2000MV/IVIM/Ribapartial/1 monthSantos 2013 \[[@gov042-B54]\]Portugal158/MGBS17 days+Serum+3a2320IVIG/MVpartial/2 monthsSharma 2013 \[[@gov042-B55]\]India127/MGBS40 days+NTNTNMIVIGFull/NMGeurtsvan-Kessel 2013 \[[@gov042-B56]\]Bangladesh1124/NMGBSNM+Serum+ in 11 in 1NMNMNMScharn 2014 \[[@gov042-B57]\]Germany150/MGBS GM1 & 1B+Concomitant+Serum+CSF--3c334IVIGFull/5 monthsvan den Berg 2014 \[[@gov042-B42]\]Netherlands10Mean: 54 6M/4FGBSMean: 5 days+Serum+ in 3 CSF-- in 53mildNMNMChen 2014 \[[@gov042-B58]\]China164/MGBS GM2+, encephalitis5 days+NTNT1461MV/IVIGFull/12 monthsComont 2014 \[[@gov042-B59]\]France173/MGBSConcomitant+Serum+CSF+3f822IVIGFull/2 monthsFong 2009 \[[@gov042-B60]\]UK153/MBilateral NAConcomitant+NTNT2547PhysiotherapyFull/2 yearsRianthavorn 2010 \[[@gov042-B61]\]Thailand149/MBilateral NA3 days+Serum+3f795NMpartial/4 monthsKamar 2011 \[[@gov042-B40]\]UK138/MBilateral NA5 days+Serum+3e1160Supportivepartial/18 monthsCarli 2012 \[[@gov042-B62]\]France130/MLeft NAConcomitant+NTNT1518SteroidFull/slowInghilleri 2012 \[[@gov042-B63]\]France128/MBilateral NAConcomitant+NTNT1007NMNMCheung 2012 \[[@gov042-B64]\]UK156/MBilateral NAConcomitant+NTNT300NMPartial/10 monthsMotte 2014 \[[@gov042-B65]\]France152/MBilateral NA7 days+Serum+3f590NMPartial/2 monthsMoisset 2014 \[[@gov042-B66]\]France136/MBilateral NA7 days+Serum+3f1707IVIG/RibaPartial/6 monthsDeroux 2014 \[[@gov042-B67]\]France138/MLeft NAConcomitant+NTNT1612NMPartial/4 monthsvan Eijk 2014 \[[@gov042-B43]\]Netherlands & UK536^1^4M/1FBilateral NANM+Serum+ in 43 in 1 pt34--313NMPartial in 5/6 monthsWoolson 2014 \[[@gov042-B41]\]UK138/MBilateral NANM+Serum +3319SupportivePartial/12 monthsUK139/MBilateral NANM+Serum +NT27SupportivePartial/12 monthsTheochari 2015 \[[@gov042-B68]\]UK165/MBilateral NAConcomitant+NTNT1368PrednisoloneFull/10 monthsDécard 2015 \[[@gov042-B69]\]Switzerland147/MBilateral NAConcomitant+NTNT106PhysiotherapyPartial/12 monthsKamar 2011 \[[@gov042-B40]\]UK142/MPRNConcomitant+Serum+CSF-3e623NMFull/3 monthsDespierres 2011 \[[@gov042-B70]\]France149/MPRNConcomitant+Serum+378SupportiveFull/2 weeksPeri 2013 \[[@gov042-B71]\]Italy153/MPRNConcomitant+Serum+Stool+31768SupportiveFull/3 monthsYadav 2002 \[[@gov042-B72]\]India113/FOculomotor palsy3 days+NTNT382SupportiveMinimalDixit 2006 \[[@gov042-B73]\]India132/MBell's palsy7 days+NTNT1000SupportiveFull/3 weeksJha 2012 \[[@gov042-B74]\]India128/MBell's palsy10 days+NTNT1200PhysiotherapyFull/3 weeksWoolson 2014 \[[@gov042-B41]\]UK192/FVestibular neuritisConcomitant+Serum+31504SupportiveFull/7 daysUK186/MNeuromyopathyConcomitant+Serum+NT285SupportivePartial/nmUK134/MSmall-fibre neuropathy2 months--Serum+CSF-NM--GabapentinNo responseBennett 2015 \[[@gov042-B75]\]UK177/FParesthesiaConcomitant+Serum+NT1606SupportiveFull/3 weeks**Acute hepatitis E -- Central manifestations**Kejariwal 2001 \[[@gov042-B76]\]India128/WMeningo-encephalitisConcomitant+NTNT1890SupportiveFull/3 weeksDeroux 2014 \[[@gov042-B67]\]France141/MEncephalitisConcomitant+Serum+ CSF+3f479NmFull/12 weeksDespierres 2011 \[[@gov042-B70]\]France154/FMeningitis Diffuse neuralgic painConcomitant+Serum+ CSF+3566Ceftriaxone/AcyclovirFull/2 weeksNaha 2012 \[[@gov042-B77]\]India133/MAseptic meningitis10 days+NTNT400SupportiveFull/nmMandal 2006 \[[@gov042-B78]\]India112/FAcute transverse myelitis20 days+NTNTNMSupportiveFull/10 daysThapa 2009 \[[@gov042-B79]\]India17/MPseudotumor cerebri2 days+NTNT654SupportiveFull/3 days**Chronic hepatitis E -- Neurological manifestations**Kamar 2010 \[[@gov042-B44]\]France144/MPyramidal syndrome, PN33 months+Serum+ CSF+3f105Reduce TAC/ IVIGDeath/3 monthsKamar 2011 \[[@gov042-B40]\]France160/MAtaxia, confusion, PRN60 months+Serum+ CSF+3f171Change TAC to sirolimusPartial/10 monthsFrance135/MEncephalitis3 years+Serum+ CSF+3f110MV/IVIG, stop IS, foscavirFull/2 monthsUK148/MSensory PNNM+Serum+ CSF+3a195PegIFN/RibaFull/7 monthsMaddukuri 2013 \[[@gov042-B80]\]USA164/MAtaxia, cognitive decline, PN12 months+Serum+3362Reduce TAC/ PegIFNDeath/48 monthsde Vries 2014 \[[@gov042-B81]\]Netherlands166/FEncephalopathy-ataxia-sensory neuropathy2 years+Serum+CSF+3299Reduce MMF/ RibaPartial/7 months[^8]

Neurological manifestations in patients with HEV infection are uncommon and have been reported as occurring in 7 cases of acute or chronic HEV infection (5.5%) over a 5-year period in a case series from Toulouse, France, and Cornwall, UK \[[@gov042-B40]\], and in 8 out of 106 cases of autochthonous acute and chronic hepatitis E (7.5%) over a 14-year period in a recent retrospective study from Cornwall, UK \[[@gov042-B41]\]. The spectrum of neurological injury is broad and can be divided into two clinical presentations: the dominant clinical presentation is peripheral nerve involvement---most commonly manifesting as Guillain-Barré syndrome (GBS)---followed by neuralgic amyotrophy (NA); the second and less frequent picture is central involvement in the form of meningitis, encephalitis, meningo-encephalitis, or transverse myelitis. Although only genotype 3 was found among patients in developed countries, cases from southern Asia were not genotyped and many of these cases could have been infected with genotype 1.

Thirty-seven cases of GBS were reported in 16 case reports and 2 case-controlled studies. In these case-controlled studies of GBS of all etiologies---involving 100 patients in Bangladesh and 201 patients in the Netherlands---acute HEV infection was associated with this syndrome in 11% and 5% of patients, respectively \[[@gov042-B42]\]. The mean age of the reported patients was 44.5 years (range 20--73) with a male-to-female ratio of 9:4. The mean delay between acute hepatitis E and neurological symptoms was 6 days (range 0--40). In 16 cases for which details of treatment were available, intravenous immunoglobulin (IVIG) was used in 13, mechanical ventilation in 5, plasmapheresis in 3 cases, and ribavirin in 1. Neurological recovery was complete in 13 cases and partial in the remaining three within a period ranging from 1 week to 18 months.

Neuralgic amyotrophy (NA), also known as brachial neuritis or Parsonage-Turner syndrome, is an acute monophasic brachial plexus disorder of unknown cause, although preceding infections have commonly been reported. Eighteen cases of NA were reported in 17 case reports and 1 case series. In this case series of 47 NA patients of all etiologies from the UK and the Netherlands, acute hepatitis E was associated with this neurological disorder in 10% of patients \[[@gov042-B43]\]. The mean age of reported patients with NA was 50 years (range 28--65) with a male-to-female ratio of 8:1. The delay between acute hepatitis E and neurological symptoms ranged from 0--7 days. NA was bilateral in 16 cases and unilateral in 2 cases (88%). In eight cases for which details of treatment were available, steroids were used in two, physiotherapy in two, IVIG and ribavirin in one case, and the treatment was supportive in three cases. Neurological recovery was complete in three cases after follow-up periods of 10--24 months, and partial in 14 cases after follow-up periods of 2--24 months.

The finding that hepatitis E is associated with both GBS and NA may suggest that these syndromes reflect differing parts of the same spectrum of neurological immune-mediated diseases \[[@gov042-B43]\].

Six cases have been reported of neurological manifestations of chronic hepatitis E following solid organ transplantation (five cases) and HIV infection (one case). HEV RNA has been found in both the serum and the cerebrospinal fluid (CSF) in the five tested patients, which suggests that HEV replication may occur in this compartment. Analysis of such HEV RNA in one patient shows that the variants differed from those observed at the same time point in the serum, which suggests the presence of neurotropic quasispecies \[[@gov042-B44]\]. The first-line therapy for chronic HEV in solid organ transplant recipients is to reduce immunosuppressants when possible. The second-line therapy in these patients is the administration of ribavirin. Full neurological recovery following treatment was noted in one patient, partial recovery in two and death, related to decompensated cirrhosis and neurological deterioration, in two. Full neurological recovery was observed in the sixth patient with HIV infection following treatment with peginterferon and ribavirin.

It is recommended that clinicians consider the possibility of HEV infection in patients with neurological disorders and concurrent transaminase elevation, especially those with peripheral nerve involvement. The diagnosis may be suggested by HEV serology but should be confirmed with molecular testing in serum, CSF, or both. The recognition of HEV infection in a patient presenting with neurological manifestations could present an opportunity to treat active HEV infection with antivirals before chronic damage takes place, but further studies are needed to clarify their role in this setting.

Musculoskeletal manifestations of HEV
=====================================

Several musculoskeletal manifestations associated with the acute phase of HEV infection have been reported: (i) asymptomatic elevation of creatine phosphokinase (CK) of MM type indicating skeletal muscle damage \[[@gov042-B82]\], (ii) acute polyarthritis lasting for 3 months and resolving spontaneously \[[@gov042-B83]\], (iii) necrotizing myositis associated with GBS in a liver-transplant patient resolving after ribavirin administration \[[@gov042-B53]\], (iv) pyomyositis 4 weeks after recovery from acute hepatitis E in a patient with recent history of type 2 diabetes \[[@gov042-B84]\], (v) inflammatory polyarthralgia revealing acute hepatitis E \[[@gov042-B85]\], and (vi) arthralgia associated with a diffuse maculopapular rash resolving with supportive measures \[[@gov042-B86]\] ([Table 4](#gov042-T4){ref-type="table"}). Further studies are needed to confirm the association of HEV infection with musculoskeletal manifestations. Table 4.Musculoskeletal manifestations associated with acute HEV infectionAuthors/yearCountryAge/sexHEV diagnosis/ genotypeManifestationsTreatmentOutcomeKitazawa 2003 \[[@gov042-B82]\]Japan59/MIgM/NTElevated CK MM typeSupportiveRecoverySerratrice 2007 \[[@gov042-B83]\]France51/WPCR/3Acute polyarthritisSupportiveRecoveryDel Bello 2012 \[[@gov042-B53]\]France65/MPCR/3fNecrotizing myositis, GBSRibavirinRecoveryAnnamalai 2013 \[[@gov042-B84]\]India39/MNMPyomyositisSurgical drainageRecoveryBialé 2013 \[[@gov042-B85]\]France40/FIgM-PCR/NTInflammatory polyarthralgiaSupportiveRecoveryAl-Shukri 2013 \[[@gov042-B86]\]UK52/FIgM-PCR/3Arthralgia, maculopapular rushsupportiveRecovery[^9]

Hematological manifestations of HEV
===================================

Hemolytic anemia
----------------

### Hemolytic anemia due to glucose-6-phosphate dehydrogenase deficiency

HEV is endemic in southern Asia, which is home to a significant proportion of glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals and instances of co-existence of both the conditions should not be rare; however, only seven case reports \[[@gov042-B31], [@gov042-B87]\] and three small case series \[[@gov042-B93]\], with a total of 17 cases, have been published of severe hemolysis occurring in patients with acute hepatitis E associated with G6PD deficiency ([Table 5](#gov042-T5){ref-type="table"}). All cases originated from southern Asia and were thought to be attributed to genotype 1. Patients presented with high-grade fever, chills, neutrophilic leukocytosis, severe hyperbilirubinemia, and renal failure---a combination that is seldom encountered in uncomplicated viral hepatitis. Their serum bilirubin ranged from 28--66 mg/dL. Acute renal failure was present in 10 patients and their serum creatinine ranged from 5.4--9.2 mg/dL, necessitating hemodialysis in seven of them. Death due to cerebral bleeding, sepsis, and hepatic failure was reported in three patients. Given the rarity of published cases, it is quite possible that more severe cases are reported, whereas less severe ones are under-diagnosed and under-reported. Wilson's disease should be ruled out in this setting, along with other causes of hemolyic anemia. Tests for G6PD deficiency may be negative during and immediately after a hemolytic episode and should be performed 8--10 weeks after the disease subsides. Administration of vitamin K should be avoided in these patients because it may further aggravate hemolysis. Renal failure may be non-oliguric; therefore, kidney function should be assessed by regularly monitoring blood chemistry, urinary sodium and osmolarity. Preventive measures against acute renal failure---such as maintenance of high urinary output, correction of fluid and electrolyte imbalance and avoidance of nephrotoxic drugs---should be implemented early. All cases of acute viral hepatitis with marked hyperbilirubinemia should be observed carefully for impaired renal function and hemolysis. However hemolysis due to G6PD deficiency is not an extrahepatic manifestation in the strict sense. Rather, instigation of hemolysis in G6PD-deficient individuals may be associated with HEV infection, as with several other infections. Table 5.Hemolytic anemia due to G6PD deficiency associated with acute HEV infection**Authors/year**CountryAge/sexHEV diagnosis/ genotypeHb (g/dL)Total bilirubin (mg/dL)Creatinine (mg/dL)TreatmentOutcomeAbid 2002 \[[@gov042-B93]\]Pakistan26/MIgM/NT6.4427.8HemodialysisRecoveryPakistan16/MIgM/NT7.2325.9SupportiveRecoveryPakistan14/MIgM/NT6.2386.4SupportiveRecoveryPakistan22/MIgM/NT6.2429.8HemodialysisRecoveryPakistan35/MIgM/NT5.5285.4SupportiveRecoveryMonga 2003 \[[@gov042-B87]\]India35/MIgM/NT848--SupportiveRecoveryZamvar 2005 \[[@gov042-B88]\]Pakistan10/FIgM/NT3.644--TransfusionRecoveryThapa 2009 \[[@gov042-B89]\]India7/MIgM/NT7.042NormalSupportiveRecoveryThapa 2009 \[[@gov042-B31]\][^a^](#gov042-TF6){ref-type="table-fn"}India7/MIgM/NT7.635--SupportiveRecoverySomani 2011 \[[@gov042-B91]\]India17/MIgM/NT5.5669.2HemodialysisRecoveryAu 2011 \[[@gov042-B94]\][^b^](#gov042-TF7){ref-type="table-fn"}China54/MIgM/NT5.850Renal failureTransfusion, hemodialysisDeath: cerebral bleedingAu 2012 \[[@gov042-B90]\]China53/MIgM/NT7.9--Renal failureTransfusion, hemodialysisDeath: sepsisChina54/MIgM/NT8.3--Renal failureHemodialysisDeath: hepatic failureJain 2013 \[[@gov042-B95]\]IndiaNMIgM/NTNM----NMRecoveryIndiaNMIgM/NTNM----NMRecoveryIndiaNMIgM/NTNM----NMRecoveryTomar 2014 \[[@gov042-B92]\]India--IgM/NT----Renal failureSupportive, hemodialysisRecovery[^10][^11][^12]

### Auto-immune hemolytic anemia

Auto-immune hemolytic anemia (AIHA) is rarely associated with viral hepatitis. HCV infection has been the main reported association, but cases of HAV and HBV have been also described \[[@gov042-B96]\]. Three documented cases of AIHA associated with HEV infection have been published \[[@gov042-B97]\]. These cases revealed sudden and rapid drops in hemoglobin levels during the course of illness and were diagnosed after excluding other causes of anemia and hemolysis. Two patients were treated supportively with good outcomes \[[@gov042-B98], [@gov042-B99]\], and the treatment administered to the third patient was not mentioned \[[@gov042-B97]\].

### Severe thrombocytopenia

A variety of hepatotropic viruses are known to cause severe thrombocytopenia. HEV infection associated with severe thrombocytopenia has been cited in six case reports \[[@gov042-B100]\] and one case series \[[@gov042-B106]\]---not necessarily in regions where the disease is endemic---with a total of nine cases ([Table 6](#gov042-T6){ref-type="table"}). The HEV genotype was not tested in all reports from southern Asia. Genotype 3 was found in patients originating from regions where HEV is not endemic. The diagnosis relies on the exclusion of other causes of thrombocytopenia. Patients\' platelet counts ranged from 1 x 10^9^/L to 21 x 10^9^/L. Most patients improved spontaneously, while others received platelet transfusion, intravenous immunoglobulin (IVIG) and/or corticosteroids. Recovery was observed in all patients and no fatalities were recorded. The mechanism of severe thrombocytopenia is believed to be immune-mediated, and platelet-associated antibodies have been positive in two out of four tested patients. It may be appropriate to perform HEV testing in patients with severe thrombocytopenia associated with elevated liver enzymes, regardless of the patient's travel history. Table 6.Severe thrombocytopenia associated with acute HEV infectionAuthors/yearAge/sexCountryHEV diagnosis/genotypeALT (IU/L)PurpuraPlatelets (/mm^3^)Anti-platelet antibodiesCo-morbidityBone marrow aspirateTreatmentOutcomeBulang 2000 \[[@gov042-B100]\][^a^](#gov042-TF8){ref-type="table-fn"}48/MGermanyIgM/NP800--18 000NTSinusitisNTSupportiveRecoveryAli 2001 \[[@gov042-B101]\][^b^](#gov042-TF9){ref-type="table-fn"}38/MIndiaIgM/NP670+10 000NegativeMGNNTIVIG, FFP, steroidsRecoverySingh 2007 \[[@gov042-B102]\]34/MIndiaIgM/NP783+13 000Positive--NormocellularIVIG, plateletsRecoveryColson 2008 \[[@gov042-B103]\]72/FFrancePCR/3f1 520--9 000NTNimesulideNormocellularSupportiveRecoveryTransient neutropeniaThapa 2009 \[[@gov042-B104]\]8/FIndiaIgM/NP1 080+21 000PositiveNormalNormo-cellularIVIGRecoveryFourquet 2010 \[[@gov042-B106]\]52/MFrancePCR/3f2 958--13 000NT--NTSupportiveRecovery20/MFrancePCR/3f461+1 000Negative--NTSteroidsRecovery61/MFrancePCR/3f1 598--10 000NT--normo-cellularSupportiveRecoveryMasood 2014 \[[@gov042-B105]\]25/MPakistanIgM/NP1045--9 000NT--normo-cellularPlateletsRecovery[^13][^14][^15]

Less-severe thrombocytopenia without significant consequences was noted in 12 out of 106 patients (11%) in a recent retrospective study of autochthonous acute and chronic hepatitis E in Cornwall, UK \[[@gov042-B41]\]. The lowest platelet count recorded at presentation in this study was 40 x 10^9^/L.

### Hepatitis-associated aplastic anemia

Hepatitis-associated aplastic anemia (HAAA) is a variant of the aplastic anemia syndrome, in which an acute attack of hepatitis leads to marrow failure and pancytopenia. It was first reported in 1955 and by 1975 more than 200 cases had been described \[[@gov042-B107]\]. HAV, HBV, HCV, hepatitis D virus (HDV), parvovirus B19, cytomegalovirus, and Epstein-Barr virus (EBV) have been associated with HAAA. Pancytopenia typically occurs 2--3 months after the hepatitis episode, which could be fulminant, acute, or chronic. The development of HAAA is always fatal if not managed promptly and the standard therapy is allogenic bone marrow transplantation from Human leukocyte antigen (HLA)-matched siblings, or immunosuppressive therapy if an appropriate donor is not available \[[@gov042-B110]\]. Two case reports of HAAA associated with HEV infection have been published, with a fatal outcome in one case and an absence of response to cyclosporine in the other \[[@gov042-B111], [@gov042-B112]\].

### Pure red cell asplasia

Pure red cell asplasia (PRCA) is a syndrome characterized by anemia, reticulocytopenia, and markedly reduced or absent erythroid progenitor cells in the bone marrow with preservation of the other hematopoietic lineages. It may present as an isolated primary hematological disorder or secondary to parvovirus infection, collagen vascular disease, leukemia, lymphoma, thymoma, solid tumors, treatment with recombinant human erythropoietin or other drugs, and pregnancy. PRCA is acute and self-limiting. One case of PRCA has been published, of a 63-year-old Chinese man with acute liver failure associated with HEV infection, who improved with supportive care \[[@gov042-B113]\].

### Secondary hemophagocytic syndrome

Secondary hemophagocytic syndrome (HPS), sometimes known as the macrophage activation syndrome, is a hyperinflammatory condition, characterized by excessive macrophage function. It is a rare, life-threatening complication of infection, hematological cancer, drug exposure, and autoimmune disease. The most common infectious trigger is EBV, but HIV is increasingly implicated, as well as other infections. There are no validated diagnostic criteria for HPS, but suggestive features include high temperatures, organomegaly, cytopenias and coagulopathy, markedly elevated ferritin levels, hypertriglyceridemia, and hypofibrinogenemia \[[@gov042-B114]\]. Four cases of HPS secondary to HEV infection have been published \[[@gov042-B115]\] ([Table 7](#gov042-T7){ref-type="table"}); high serum ferritin level was noted in all cases. Co-morbidities were observed in three cases (hepatitis A co-infection, splenic lymphoma, and rheumatoid arthritis treated with tocilizumab infusion; these could have played a role in the occurrence of hemophagocytic syndrome, due to known associations). Three patients recovered with supportive treatment, and the fourth died due to fulminant hepatitis. Table 7.Hemophagocytic syndrome secondary to HEV infectionAuthors/yearAge/sexCountryHEV diagnosis/genotypeCo-morbidityBone marrow aspirateHemoglobin (mg/dL)Leucocytes (/mm^3^)Platelets (/mm^3^)Ferritin ng/mLTreatmentOutcomeKamihira 2008 \[[@gov042-B115]\]52/MJapanPCR/3----14.32 80020 00023 200SupportiveRecoveryKaur 2011 \[[@gov042-B117]\]6/FIndiaIgM/NTHAV co-infection, hepatic encephalopathyHPC6.2--180 0001 923SteroidsDeathBrun 2013 \[[@gov042-B116]\]32/MFranceIgM/NTSplenic lymphomaNormalLowLowLow2 452SupportiveRecoveryLeroy 2005 \[[@gov042-B118]\]33/MFranceIgM, PCR/NTRheumatoid arthritis, tocilizumab infusionHPC----63 0008 856SupportiveRecovery[^16]

### Other hematological manifestations

Monoclonal gammopathy of undetermined significance (MGUS), without clinical or laboratory findings suggestive of myeloma or lymphoma, was noted in 17 out of 65 patients (26%) in a recent retrospective study of autochthonous acute and chronic hepatitis E in Cornwall, UK; however, bone marrow biopsy---which allows differentiation between MGUS and monoclonal gammopathy secondary to viral infections---was not performed in these patients \[[@gov042-B119]\]. Paraproteinemia disappeared in three out of six patients after a median of 44.5 months with follow-up serum electrophoresis.

One case of HEV-associated severe agranulocytosis was reported in a 70-year-old Spanish patient infected with genotype 3, with fatal outcome despite treatment with granulocyte-colony stimulating factor and a broad-spectrum antibiotic \[[@gov042-B120]\].

Renal manifestations of HEV and cryoglobulinemia
================================================

Renal manifestations
--------------------

HEV infection has recently been reported to be associated with renal manifestations. A statistically---but not clinically---significant decrease of estimated glomerular filtration rate (eGFR,-5 mL/min) has been described in France in 51 transplant patients during the acute phase of HEV infection genotype 3 \[[@gov042-B121]\]. The decrease appeared to be related to HEV, since other causes were ruled out (e.g. acute rejection, infection, modification in immunosuppression regimen). One case of HEV-related acute tubular necrosis has been reported in an immunocompetent patient who was successfully treated with steroids \[[@gov042-B122]\]. Two cases of acute renal failure of unknown cause, in association with HEV infection, were reported, one case in a kidney transplant patient who recovered with supportive treatment \[[@gov042-B123]\], and a second case in an Indian patient with severe hyperbilirubinemia that responded to hemodialysis \[[@gov042-B124]\]. Renal biopsy was not done in either of these cases. Finally, at least eight cases of glomerulonephritis, associated with nephrotic syndrome and/or mixed cryoglobulinemia, have been described \[[@gov042-B101], [@gov042-B121]\] ([Table 8](#gov042-T8){ref-type="table"}). Types of renal injury included membranoproliferative glomerulonephritis, membranous nephropathy, relapsing IgA nephropathy, and nephroangiosclerosis; seven of these cases occurred in immunosuppressed patients. Immunosuppressant dose reduction or antiviral administration led to complete recovery in three patients and stabilization in one, whereas end-stage renal disease occurred in three patients. It is noteworthy that six out of eight cases of glomerulonephritis were published by the Toulouse group \[[@gov042-B121], [@gov042-B124], [@gov042-B125]\] which raises the possibility that other cases may have gone undetected elsewhere. The mechanism of HEV-induced kidney disease could be immune-driven in a manner similar to that with HCV. HEV should be screened for in cases of glomerulonephritis, especially if it is associated with transaminase elevation. Ribavirin can then be used to obtain a rapid viral clearance. Table 8.Renal manifestations associated with HEV infectionAuthors/yearAge/sexCountryHEV diagnosis/genotypeAssociated diseaseRenal manifestationsTreatmentOutcomeVerschuuren 1997 \[[@gov042-B122]\]34/FNetherlandsIgM/NTNoneATN (unknown cause)SteroidsRecoveryAli 2001 \[[@gov042-B101]\]38/MIndiaIgM/NTNoneMGNSteroidsRecoveryKamar 2005 \[[@gov042-B123]\]28/MFrancePCR/NTRenal transplantRenal failure (unknown cause), no renal biopsySupportiveRecoveryKamar 2012 \[[@gov042-B121]\]33/MFrancePCR/3fRenal transplantMPGN, NSTAC reductionRecovery26/MFrancePCR/3fRenal transplantIGAN relapse, MC II, NSRibavirinStable40/MFrancePCR/3fRenal transplantIGAN relapse, MC II, NSTAC reductionEnd stage renal disease end stage renal disease24/MFrancePCR/3fRenal transplantMPGN, MC III, NSRituximabEnd stage renal disease58/MFrancePCR/3cLiver transplantNAS, MC III, NSPegIFNVikrant 2013 \[[@gov042-B124]\]56/MIndiaIgM/NTSevere hyperbilirubinemiaRenal failure (unknown cause), no renal biopsyHemodialysisImprovement, Sudden CV arrestTaton 2013 \[[@gov042-B125]\]60/MFrancePCR/3cRenal transplantMN, NSRibavirinRecoveryKamar 2015 \[[@gov042-B123]\]46/MFrancePCR/3fRenal transplantMPGN, MCTAC reduction, ribavirinRecoveryDel Bello 2015 \[[@gov042-B126]\]46/MFrancePCR/3fRenal transplantMPGNTAC reduction, ribavirinRecovery[^17]

Mixed cryoglobulinemia
----------------------

Mixed cryoglobulinemia has been associated with several viral infections; at least nine viruses have been implicated \[[@gov042-B127]\]. HCV chronic infection is recognized as the major cause of mixed cryoglobulinemia, reported in 90% of Italian patients in one series \[[@gov042-B128]\], although later studies found wide geographical variations \[[@gov042-B129]\]. Some cases of mixed cryoglobulinemia are related to HIV \[[@gov042-B130]\], HBV \[[@gov042-B131]\] and, less frequently, to HAV \[[@gov042-B132]\], as well as other viruses.

Four reports of HEV-related mixed cryoglobulinemia, associated with glomerulonephritis and/or nephrotic syndrome, have been published, with a total of 11 patients \[[@gov042-B121], [@gov042-B126], [@gov042-B133], [@gov042-B134]\] ([Table 9](#gov042-T9){ref-type="table"}). In one of these cases, HCV-HEV co-infection was present, and HEV RNA was not tested, which makes this case a probable HEV-related mixed cryoglobulinemia \[[@gov042-B133]\]. In the other 10 cases, HEV-related mixed cryoglobulinemia was well documented. In all cases published thus far, the presence of HEV RNA in the cryoprecipitate was not evaluated. Table 9.Mixed cryoglobulinemia associated with HEV infectionAuthors/yearNo. of casesCountryAge/sexCo-morbidityCryoglobulinemiaHEV infectionTypeManifestationDiagnosis/genotypeTreatmentOutcomeMarson 1995 \[[@gov042-B133]\]1Italy62/FHCV co-infectionIIPeripheral neuropathyIgG/NMNMNMKamar 2012 \[[@gov042-B121]\]8FranceNMSolid organ transplantationII--IIIGlomerulonephritis, nephrotic syndromePCR/3PegIFN or ribavirinNegative PCR 3 month after beginning of treatment, but SVR not reportedPischke 2014 \[[@gov042-B134]\]1Germany35/MLiver transplantIIIArthralgia, myalgia, thrombocytopeniaPCR/NMSteroidsDeath (mucositis)Del Bello 2015 \[[@gov042-B126]\]1France46/MRenal transplantIIIMPGNPCR/3fTAC reduction then ribavirinSVR, recovery[^18]

HEV-related mixed cryoglobulinemia occurred during active infection in 9 cases or after viral clearance in one case \[[@gov042-B134]\]. The occurrence of mixed cryoglobulinemia after viral clearance is similar to what has been observed in other extra-hepatic manifestations related to HEV infection. As with other viral infections, HEV could trigger autoimmunity, which could explain the development of extra-hepatic manifestations after viral clearance \[[@gov042-B135]\]. All reported patients with mixed cryoglobulinemia (i) were immunosuppressed because of solid organ transplantation, (ii) had chronic hepatitis E with persistent HEV replication for more than 3 months, and (iii) originated from western Europe, where genotype 3 is prevalent, with confirmation of this genotype in nine patients. All patients had type II or III mixed cryoglobulinemia. Antiviral treatment (peginterferon or ribavirin) was given in nine cases. Viral clearance and negativity of cryoglobulinemia were obtained in all patients 3 months after the beginning of antiviral treatment. Similarly, rheumatoid factor, when present, disappeared and the C3 complement component was slightly decreased during antiviral therapy. Immunosuppressive treatment was given in one case (steroids and increase of immunosuppressants) with rapid symptomatic improvement; however, two relapses occurred after reduction of corticosteroids. During the second relapse, the patient developed an acute, fatal episode of severe intestinal mucositis.

HEV infection should be added to the other viral infections causing mixed cryoglobulinemia \[[@gov042-B136]\]. Further studies are needed to delineate the frequency of HEV-related mixed cryoglobulinemia, its pathophysiology, and to confirm in a larger cohort of patients the excellent---albeit preliminary---data on antiviral treatment.

Other possibly immune-mediated manifestations
---------------------------------------------

Six cases of thyroid diseases (three cases of Grave's disease, one of subclinical hyperthyroidism, one of subacute thyroiditis, and one of painless thyroiditis) have been published \[[@gov042-B137]\]. It was suggested that HEV might be a trigger for the development of autoimmune thyroiditis \[[@gov042-B137]\]. Three cases of HEV-related myocarditis have been published, with full recovery either spontaneously or following treatment with indomethacin or steroids \[[@gov042-B142]\]. One case of Schöenlein-Henoch purpura, which resolved itself spontaneously after clearance of the virus \[[@gov042-B145]\], and another case of *myasthenia gravis,* which resolved itself after treatment with ribavirin and intravenous immunoglobulin \[[@gov042-B146]\], have also been reported ([Table 10](#gov042-T10){ref-type="table"}). Further studies are needed to confirm these associations. Table 10.Other possibly autoimmune extra-hepatic manifestations associated with acute HEV infectionAuthors/yearCountryAge/sexHEV diagnosis /genotypeManifestationsTreatmentOutcome**Thyroid diseases**Hui 2003 \[[@gov042-B139]\]Hong Kong, China38/MIgG-IgM/NTInactive HBsAg carrier, Grave's disease, fulminant hepatitisLithium, methimazoleRecoveryKong 2006\[[@gov042-B138]\]South Korea34/FIgG-IgM/NTSubclinical hyperthyroidismPTURecoverySouth Korea42/MIgG-IgM/NTGrave's diseaseintractable to PTURecoveryDumoulin 2012 \[[@gov042-B137]\]GermanyNM/WIgM/NTGrave's diseaseCarbimazol, radioiodineRecoveryMartinez-Artola 2015 \[[@gov042-B140]\]Argentina45/MIgG-IgM/3aSubacute thyroiditisSupportiveRecoveryInagaki 2015 \[[@gov042-B141]\]Japan65/FPainless thyroiditis, severe hepatitisSteroidRecovery**Myocarditis**Goyal 2009 \[[@gov042-B142]\]India21/MIgM/NTDyspnea, hypotension, acidosisVentilation, steroids inotropic support,RecoveryDougherty 2012 \[[@gov042-B143]\]USA50/FIgM/NTChest pain, palpitations, dyspneaIndomethacinRecoveryPremkumar 2015 \[[@gov042-B144]\]India26/MIgM/NTAcute kidney injurySupportive, SLEDRecovery**Other manifestations**Thapa 2010 \[[@gov042-B145]\]India6/FIgM/NTSchöenlein, Henoch purpuraSupportiveRecoveryBelbezier 2014 \[[@gov042-B146]\]France33/WRNA/3fMyasthenia gravis, anti musk+prostigmine, IVIG, ribavirinRecovery[^19]

Conclusion
==========

Numerous extra-hepatic manifestations have been described in patients with HEV infection, mostly as case reports or small case series. Most of these reports were published during the last 5 years, which reflects increased awareness of HEV infection in regions where the disease is not endemic, as well as increased awareness of the extra-hepatic manifestations associated with this infection in general. Acute pancreatitis, neurological disorders with predominantly peripheral nerve involvement, hemolytic anemia due to G6PD deficiency, severe thrombocytopenia, glomerulonephritis, and mixed cryoglobulinemia are the most frequent. For several manifestations, there is a possibility that the association was conjectural. One needs to distinguish between anti-HEV IgM positivity and actual clinical illness resembling hepatitis. Such critical evaluation was not feasible. The other extra-hepatic manifestations are uncommonly reported. They may develop either in acute or chronic infection, and during active infection or after clearance of HEV infection. Unless a diagnosis of HEV infection is specifically sought, the diagnosis will be missed because the clinical presentations overlap with many other disorders. We anticipate that more extra-hepatic manifestations of HEV will be reported in the future and that a greater understanding of their immuno-pathogenesis and treatment will evolve.

We are grateful to Dr. Sudhamshu for providing us with supplementary information regarding his prospective study of acute pancreatitis associated with HEV infection.
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[^1]: eGFR = estimated glomerular filtration rate; G6PD = glucose-6-phosphate dehydrogenase; MGUS = monoclonal gammopathy of uncertain significance

[^2]: ^a^Days between jaundice and acute pancreatitis

[^3]: ^b^Days in hospital after diagnosis of AP

[^4]: ^c^Indian patient living in Poland with recent travel to India

[^5]: ^d^G6PD deficiency patient

[^6]: ^e^Pakistani-French patient living in France with recent travel to Pakistan

[^7]: NM=not mentioned; NT=not tested

[^8]: ALT=alanine aminotransferase; CSF=cerebrospinal fluid; GBS=Guillain-Barré syndrome; IS = immunosuppressants; IVIG = intravenous immunoglobulin; MMF = mycophenolate mofetil; MV = mechanical ventilation; NA = neuralgic amyotrophy; NM = not mentioned; NT = not tested; PN = peripheral neuropathy; PegIFN = pegylated interferon; PP = plasmapheresis; PRN = polyradiculoneuropathy; Riba = ribavirin; TAC = tacrolimus

[^9]: CK = creatine phosphokinase; GBS = Guilain-Barré syndrome; NM = not mentioned; NT = not tested

[^10]: ^a^Patient with associated acute pancreatitis

[^11]: ^b^Patient with raised methemoglobinemia

[^12]: G6PD = glucose-6-phosphate dehydrogenase; NM = not mentioned; NT = not tested

[^13]: ^a^Indian patient living in Germany with recent travel to India

[^14]: ^b^Patient with membranous glomerulonephritis

[^15]: FFP = fresh frozen plasma; IVIG = intravenous immunoglobulin; MGN = membranous glomerulonephritis; NT = not tested

[^16]: HPC = hemophagocytosis; NT = not tested

[^17]: ATN = acute tubular necrosis; CV = cardiovascular; IGAN = IgA nephropathy; MGN = membranous glomerulonephritis; MC = mixed cryoglobulinemia; MN = membranous nephropathy; MPGN = membranoproliferative glomerulonephritis; NAS = nephroangiosclerosis; NS = nephrotic syndrome; NT = not tested; PegIFN = pegylated interferon; TAC = tacrolimus

[^18]: MPGN = membranoproliferative glomerulonephritis; NM = not mentioned; PegIFN = pegylated interferon; TAC = Tacrolimus; SVR = sustained virological response

[^19]: IVIG: intravenous immunoglobulin; MuSK: muscle specific kinase; NT: not tested; PTU: propyltuiouracil; SLED: slow low efficiency dialysis
